You're Telling Us...

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2008
Volume 32
Issue 2

PharmTech's polls feature user feedback on issues facing the pharmaceutical industry.

The editors at Pharmaceutical Technology worked hard last month developing ways to improve our online offerings, from the launch of a new Equipment & Processing report to a redesigned weekly enewsletter (ePT) to the creation of PharmTech Polls. This new feature on pharmtech.com is a way to give you, our readers, a voice online and allow you to weigh in on important industry topics.

Alexis Brekke

So far, voters have shared their definitions of "design space," predictions for the future of inhalation drug delivery, concerns about over-the-counter (OTC) children's medications, options for reforming the US Food and Drug Administration's foreign inspections process, speculations on the industry's focus in 2008, and more.

Your feedback is often honest and insightful. One user described "design space" as "just a new buzzword for defining the acceptable range of a product and process, which is something an optimization program should have done for many years now."

In response to our question on standardizing dosing devices for OTC children's medications, which all respondents supported, one user said these medications and devices should be sold in the same manner as pseudoephedrine formulations—directly by a pharmacist.

A comment stemming from our inhalation delivery poll says "the science to deliver macromolecules for systemic absorption has been pushed too rapidly by a selected few in the 'aerosol delivery' scientific community," warning that the implications of this delivery method on the lungs are not completely understood.

We look forward to hearing more input from you. Share your views with us at pharmtech.com/polls.

Alexis Brekke is an assistant editor of Pharmaceutical Technology, abrekke@advanstar.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development